For research use only. Not for therapeutic Use.
Dabigatran etexilate (Cat.No:I002632) is an oral anticoagulant used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. It works by inhibiting thrombin, an enzyme involved in blood clotting. Dabigatran etexilate offers an alternative to traditional anticoagulants with simplified dosing and fewer drug interactions.
Catalog Number | I002632 |
CAS Number | 211915-06-9 |
Synonyms | ethyl 3-[[2-[[4-[(Z)-N/’-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate |
Molecular Formula | C34H41N7O5 |
Purity | ≥95% |
Target | Thrombin |
Solubility | DMSO ≥121mg/mL Water <1.2mg/mL Ethanol ≥53mg/mL |
Storage | 3 years -20℃ powder |
IC50 | 4.5 nM (Ki); 10 nM(Thrombin-induced platelet aggregation) [1] |
IUPAC Name | ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate |
InChI | InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) |
InChIKey | KSGXQBZTULBEEQ-UHFFFAOYSA-N |
SMILES | CN1C2=CC=C(C(N(CCC(OCC)=O)C3=NC=CC=C3)=O)C=C2N=C1CNC4=CC=C(C(NC(OCCCCCC)=O)=N)C=C4 |
Reference | </br>1:Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate. Wolfe AR, Faroqui RM, Visvikis GA, Mantello MT, Perel AB, Tewari SO.Radiol Case Rep. 2017 Mar 22;12(2):257-260. doi: 10.1016/j.radcr.2017.02.004. eCollection 2017 Jun. PMID: 28491164 Free PMC Article</br>2:Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report. Tireli D, He J, Nordling MM, Wienecke T.J Stroke Cerebrovasc Dis. 2017 May 4. pii: S1052-3057(17)30154-4. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.039. [Epub ahead of print] PMID: 28479184 </br>3:Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients. Molteni M, Bo M, Di Minno G, Di Pasquale G, Genovesi S, Toni D, Verdecchia P.Intern Emerg Med. 2017 Jun;12(4):425-435. doi: 10.1007/s11739-017-1660-6. Epub 2017 Apr 24. Review. PMID: 28439778 </br>4:A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery. Mayer A, Schuster P, Fink B.Arch Orthop Trauma Surg. 2017 Jun;137(6):797-803. doi: 10.1007/s00402-017-2697-8. Epub 2017 Apr 24. PMID: 28439702 </br>5:Novel dabigatran etexilate hemisuccinate-loaded polycap: Physicochemical characterisation and in vivo evaluation in beagle dogs. Cho JH, Kim JC, Kim HS, Kim DS, Kim KS, Kim YI, Yong CS, Kim JO, Youn YS, Oh KT, Woo JS, Choi HG.Int J Pharm. 2017 Jun 15;525(1):60-70. doi: 10.1016/j.ijpharm.2017.04.028. Epub 2017 Apr 13. PMID: 28414137 </br>6:Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Blair HA, Keating GM.Drugs. 2017 Mar;77(3):331-344. doi: 10.1007/s40265-017-0699-z. Review. PMID: 28185082 </br>7:Impact of Pharmacists/’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study. Shimizu T, Momose Y, Ogawa R, Takahashi M, Echizen H.J Pharm Health Care Sci. 2017 Jan 17;3:4. doi: 10.1186/s40780-017-0077-8. eCollection 2017. PMID: 28116115 Free PMC Article</br>8:Dabigatran etexilate in a vitamin-K antagonist non responder patient during Heartware HVAD support. Baronetto A, Centofanti P, Attisani M, Boffini M, Ricci D, Simonato E, Rinaldi M.J Card Surg. 2017 Feb;32(2):166-167. doi: 10.1111/jocs.13097. Epub 2017 Jan 17. PMID: 28097728 </br>9:The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. Di Minno MN, Ambrosino P, Di Minno A, Tremoli E, Di Minno G.Ann Med. 2017 Jun;49(4):329-342. doi: 10.1080/07853890.2016.1268710. Epub 2017 Jan 13. PMID: 28084107 </br>10:Development of Left Atrial Thrombus After Coadministration of Dabigatran Etexilate and Phenytoin. Hager N, Bolt J, Albers L, Wojcik W, Duffy P, Semchuk W.Can J Cardiol. 2017 Apr;33(4):554.e13-554.e14. doi: 10.1016/j.cjca.2016.10.022. Epub 2016 Oct 28. PMID: 28063739 |